

Company name: Inner Cosmos

Website: <https://innercosmos.ai/>

CEO: Meron Gribetz

COO (presenter): Aharon Grossman

CATEGORY: Medical Devices

SESSION: Beyond Neuropharma and Neurotech: Integrated Brain Control.

- **Executive Summary / Investment Rationale**

Inner Cosmos is a neurotechnology company pioneering psychiatric brain-computer interfaces (BCIs) for Treatment-Resistant Depression (TRD). Its minimally invasive "Digital Pill" targets a \$50B+ global depression market. The company has raised \$13.2M, secured FDA IDE approval, and implanted three subjects with promising clinical outcomes. Co-founders include CEO Meron Gribetz, Washington University neurosurgeon Dr. Eric Leuthardt, and Harvard/MGH psychiatrist Dr. Darin Dougherty.

- **Core Technology**

The Digital Pill is a penny-sized device embedded in the skull that delivers targeted neurostimulation similar to Transcranial Magnetic Stimulation (TMS), the most efficacious treatment for depression today, Inner Cosmos's therapy rebalances dysfunctional brain networks, without the need for daily clinic visits, enabling ongoing home-based psychiatric treatment. The Digital Pill is minimally invasive, making it safer than other BCIs.

- **Product Profile / Pipeline**

Inner Cosmos has completed an FDA-approved Early Feasibility Study for TRD. All three subjects implanted to date have surpassed their prior best TMS outcomes, with two achieving remission. The pipeline extends to mild and major depression and other cognitive disorders, including Alzheimer's, PTSD, addiction, and more.

- **Business Strategy**

Inner Cosmos will generate revenue primarily through direct sales of the implanted Digital Pill device. Initial commercialization targets TRD with a device cost of \$35,000, a compelling value versus the cumulative cost of ongoing TMS sessions. Ease of at-home administration, increased patient compliance, and better therapeutic outcomes will drive market acceptance and enable label expansion to new indications.

- **What's Next?**

Inner Cosmos will publish peer-reviewed results for its Early Feasibility Study, initiate a 10-15 subject pilot trial for TRD, followed by a pivotal trial. In parallel, the company is finalizing the development of the Digital Pill for market entry. Financially, Inner Cosmos is raising an additional Seed round to fund development and expand trials.